NCT00603499

Magnesium and Metabolic Syndrome

Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Instituto Mexicano del Seguro Social · Other Government
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension. Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo. Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile

Conditions

• Diabetes Mellitus
• High Blood Pressure
• Hypomagnesemia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Magnesium chloride	Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
OTHER	Placebo	Subjects in the control group received inert placebo once per day during 4 months

Timeline

• Start date: 2006-07-01
• Primary completion: 2007-08-01
• Completion: 2007-11-01
• First posted: 2008-01-29
• Last updated: 2008-01-29

Locations

1 site across 1 country: Mexico